Meiji Seika Kaisha, Ltd.

Meiji Seika Pharma Co., Ltd.

Yuji Tabata

Takeru Yamakawa

Takashi Matsuhira

Yasushi Kurata

Kenichi Kurihara

Tsuneo Okonogi

Takashi Yaguchi

Keiji Tamura

Kiyoshi Tanabe

Naoko Miike

Natsuki Ishida

Ayako Someya

Masahiro Hatsu

Rie Shinei

Satoshi Isshiki

Kaori Kaneda

Yoshinari Wakiyama

Shohei Ouchi

Makoto Suzuki

Naoyuki Nishikawa

Toru Sasaki

Yasuo Yamamoto

Naomi Masuda

Keiichi Ajito

Kazunobu Takahashi

Chika Kikuchi

Kenji Asai

Shohei Yasuda

Maiko Iida

Masaharu Sugai

Makoto Ohyama

Kenzo Harimaya

Naoko Watanabe

Fukuichi Ohsawa

Jiro Tanaka

Sho Takahata

Akihiko Ikegawa

Kozo Aoki

Nobukazu Kakui

Natsuki Kubota

Kaori Miyajima

Kuniaki Tatsuta

Emiko Magome

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1),

Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1),

Compound and pharmacologically acceptable salt thereof

Provided is a compound represented by formula (1a) or a pharmacologically acceptable salt thereof, which can be used as a phosphodiesterase (PDE) inhibitor. Rto Rin the formula each independently represent an alkyl group or the like. 

PDE4 inhibitor

An anti-fungal agent for tinea comprising as active ingredient a compound having the skeleton of 2-(1H-pyrazol-1-yl)phenol represented by the following formula (I) or (II) or a salt thereof is provided 

Topical antifungal agent

A compound represented by the formula (I) &lsqb;A represents a 5- to 7-membered hydrocarbon ring group; L represents &mdash;NR &mdash;CO&mdash;, &mdash;CO&mdash;NR &mdash; and the like (R represents a hydrogen atom, a lower alkyl group, a lower acyl group and the like); M represents an alkylene linking group (a carbon atom constituting the carbon chain may be replaced with a nitrogen atom, an oxygen atom and the like); X represents &mdash;S&mdash;, &mdash;O&mdash;, &mdash;NR &mdash;, &mdash;NR &mdash;CO&mdash; and the like (R and R represent a hydrogen atom, a lower alkyl group and the like) or a single bond; Y represents an alkyl group, an aryl group, an amino group, an aromatic heterocyclic group and the like; R represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a lower acyl group; and R , R and R represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like&rsqb; or a salt thereof. The compound is useful as an active ingredient of medicaments for diseases in which neuropeptide Y is involved, ingestion control for hyperphagia and the like.

Tricyclic compounds

Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic agents for progesterone-related diseases. Specifically, they are useful as abortifacients, oral contraceptive pills, carcinostatic agents for breast cancer and ovarian cancer, therapeutic agents for endometriosis, meningioma, and myeloma, and therapeutic and prophylactic agents for osteoporosis and climacteric disturbance.

Tetrahydronaphthofuranone derivatives and process for producing the same

Tetrahydrobenzindolone derivatives

Sesquiterpene derivatives, represented by the following formulae (I) and (II), having progesterone receptor binding inhibitory activity are disclosed. They can be used as therapeutic and prophylactic agents for progesterone-related diseases, for example, as a carcinostatic agent for breast cancer or ovarian cancer, a therapeutic agent for hysteromyoma, endometriosis, meningioma, or myeloma, an abortifacient, an oral contraceptive pill, or a therapeutic or prophylactic agent for osteoporosis or climacteric disturbance. These compounds have no steroid skeleton and, hence, are considered to be advantageously free from side effect inherent in steroid such as found in conventional progesterone receptor binding inhibitors having a steroid skeleton. ##STR1## wherein R.sup.1 represents a hydrogen atom, a halogen atom, C.sub.1 -C.sub.5 alkoxy, or phenylthio; R.sup.2 represents C.sub.1 -C.sub.5 alkoxy or C.sub.2 -C.sub.5 alkanoyloxy; and ---- with letters a, b, c, d, and e attached thereto represent a double bond or a single bond; R.sup.3 has the same meaning as R.sup.2 ; and R.sup.4 represents C.sub.1 -C.sub.5 alkoxy.

Sesquiterpene derivatives having progesterone receptor binding

This invention provides novel physiologically active substances PF1092A, PF1092B and PF1092C, which can inhibit binding of progesterone to progesterone receptor. These substances were obtained by culturing a fungal microorganism belonging to the genus Penicillium using a medium containing ordinary nutrients for microorganisms and isolating the physiologically active substances PF1092A, PF1092B and PF1092C from the resulting culture mixture by means of solvent extraction, silica gel column chromatography, and the like. Molecular formulae of the novel physiologically active substances PF1092A, PF1092B and PF1092C are C.sub.17 H.sub.20 O.sub.5, C.sub.17 H.sub.20 O.sub.5 and C.sub.15 H.sub.18 O.sub.4, respectively.

Physiologically active substances PF1092A, PF1092B and PF1092C, process

Physiologically active substances PF1092A, PF1092B and PF1092C, and

Growing community of inventors

Yokohama, Japan

Yuji Tabata